单词 | raltegravir | ||||||||
释义 | raltegravirraltegravirraltegravirPharmacologic class: Human immunodeficiency virus (HIV) integrasestrand transfer inhibitor Therapeutic class: Antiretroviral Pregnancy risk category C ActionRapidly blocks HIV integrase (enzyme needed for HIV replication), leading to viral load reduction and increased CD4+ count AvailabilityTablets (chewable): 25 mg, 100 mg Tablets (film-coated): 400 mg Indications and dosages➣ HIV-1 infection in adults used in combination with other antiretrovirals Adults and adolescents ages 12 and older: 400 mg film-coated tablet P.O. b.i.d. Children age 6 to younger than age 12 weighing at least 25 kg (55 lb): One 400-mg film-coated tablet P.O. b.i.d. or chewable tablets, weight based to maximum of 300 mg P.O. b.i.d. Children age 6 to younger than age 12 weighing less than 25 kg (55 lb): Chewable tablets, weight based to maximum of 300 mg P.O. b.i.d. Children age 2 to younger than age 6 weighing at least 10 kg (22 lb): Chewable tablets, weight based to maximum of 300 mg P.O. b.i.d. ContraindicationsNone PrecautionsUse cautiously in: • treatment-naive adults (safety and efficacy not established) • increased risk of myopathy or rhabdomyolysis (such as with concomitant use of drugs known to cause these conditions) • elderly patients • pregnant patients • breastfeeding patients (use not recommended) • children younger than age 2 (safety and efficacy not established). Administration• Administer with or without food. • Be aware that film-coated tablets can't be substituted with chewable tablets. ![]() Adverse reactionsCNS: headache, fatigue, asthenia, dizziness, insomnia CV: myocardial infarction GI: nausea, vomiting, diarrhea, abdominal pain, gastritis GU: toxic nephropathy, renal failure, renal tubular necrosis Hematologic: anemia, neutropenia Hepatic: hepatitis Musculoskeletal: myopathy, rhabdomyolysis Skin: lipodystrophy, Stevens-Johnson syndrome, toxic epidermal necrolysis Other: fever, herpes simplex, immune reconstitution syndrome, hypersensitivity reaction InteractionsDrug-drug. Strong UGT1A1 inducers (such as rifampin): reduced raltegravir blood level UGT1A1 inhibitors (such as atazanavir): increased raltegravir blood level Drug-diagnostic tests. Absolute neutrophil count, hemoglobin, platelets: decreased levels ALP, ALT, AST, blood glucose, creatine kinase, lipase, pancreatic enzymes, total bilirubin: increased levels Patient monitoring• Monitor renal function tests. • Be aware that immune reconstitution syndrome has occurred in patients receiving drug with combination antiretroviral therapy. During initial phase of therapy, patient whose immune system responds may develop inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jiroveci pneumonia, or tuberculosis), which may necessitate further evaluation and treatment. • Be aware that severe, potentially life-threatening and fatal skin reactions have been reported, including Stevens-Johnson syndrome, hypersensitivity reaction, and toxic epidermal necrolysis. Immediately discontinue drug if severe hypersensitivity, severe rash, or rash with systemic symptoms or liver aminotransferase elevations develops. Closely monitor clinical status, including liver aminotransferases. Patient teaching• Tell patient drug may be taken with or without food. • Inform patient with phenylketonuria that chewable tablets contain phenylalanine. • Inform patient that drug doesn't cure HIV infection or reduce risk of passing it to others through sexual contact, needle sharing, or blood exposure. See Advise patient to immediately report muscle weakness, urinary problems, new infections, rash, fever, general malaise, swelling of face or throat, or chest pain. • Instruct female patient to notify prescriber if she is pregnant or intends to become pregnant. • Caution breastfeeding patient to discontinue breastfeeding while taking drug, because of potential HIV transmission and adverse reactions in infants. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. raltegravir(ral-teg-ra-veer) raltegravir,Isentress(trade name)ClassificationTherapeutic: antiretroviralsPharmacologic: integrase strand transfer inhibitors instis IndicationsActionTherapeutic effectsPharmacokineticsTime/action profile (blood levels)
Contraindications/PrecautionsAdverse Reactions/Side EffectsCentral nervous system
Cardiovascular
Gastrointestinal
Genitourinary
Hematologic
Metabolic
Dermatologic
Musculoskeletal
Miscellaneous
InteractionsDrug-Drug interactionConcurrent use with strong inducers of the UGT A1A enzyme system including rifampin may ↓ blood levels and effectiveness.Concurrent use with strong inhibitors of the UGT A1A enzyme system including atazanavir may ↑ blood levels.↑ risk of rhabomyolysis/myopathy HMG-CoA reductase inhibitors.Proton pump inhibitors may ↑ levels.Efavirenz, etravirine, and tipranavir/ritonavir may ↓ levels.Administration with antacids, containing magnesium, aluminum, or calcium ↓ absorption of tipranavir; separate administration of tipranavir and magnesium- or aluminum-containing antacids by ≥2 hr.Route/DosageAvailabilityNursing implicationsNursing assessment
Potential Nursing DiagnosesRisk for infection (Indications)Noncompliance (Patient/Family Teaching) Implementation
Patient/Family Teaching
Evaluation/Desired Outcomes
raltegravirAn HIV-1 integrase inhibitor drug that is expected to become an important component of combined therapy for AIDS. Integrase is one of three enzymes essential for HIV replication. |
||||||||
随便看 |
|
英语词典包含2567994条英英释义在线翻译词条,基本涵盖了全部常用单词的英英翻译及用法,是英语学习的有利工具。